CA3188752A1 - Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection - Google Patents

Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection

Info

Publication number
CA3188752A1
CA3188752A1 CA3188752A CA3188752A CA3188752A1 CA 3188752 A1 CA3188752 A1 CA 3188752A1 CA 3188752 A CA3188752 A CA 3188752A CA 3188752 A CA3188752 A CA 3188752A CA 3188752 A1 CA3188752 A1 CA 3188752A1
Authority
CA
Canada
Prior art keywords
dihydro
oxazine
oxo
carboxamide
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3188752A
Other languages
English (en)
French (fr)
Inventor
Matthew Barrett
George Stuart Cockerill
James Good
Craig Alex AVERY
Edward James COCHRANE
Stefan Paul JONES
Stuart Thomas Onions
Andrew Joseph WARNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA3188752A1 publication Critical patent/CA3188752A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3188752A 2020-07-07 2021-07-07 Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection Pending CA3188752A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2010409.7 2020-07-07
GBGB2010409.7A GB202010409D0 (en) 2020-07-07 2020-07-07 Pharmaceutical compounds
PCT/GB2021/051731 WO2022008911A1 (en) 2020-07-07 2021-07-07 Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection

Publications (1)

Publication Number Publication Date
CA3188752A1 true CA3188752A1 (en) 2022-01-13

Family

ID=72050502

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3188752A Pending CA3188752A1 (en) 2020-07-07 2021-07-07 Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection

Country Status (10)

Country Link
US (1) US12678446B2 (cg-RX-API-DMAC7.html)
EP (1) EP4178964A1 (cg-RX-API-DMAC7.html)
JP (1) JP7840923B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230035597A (cg-RX-API-DMAC7.html)
CN (1) CN116075516B (cg-RX-API-DMAC7.html)
BR (1) BR112023000142A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188752A1 (cg-RX-API-DMAC7.html)
GB (1) GB202010409D0 (cg-RX-API-DMAC7.html)
MX (1) MX2023000440A (cg-RX-API-DMAC7.html)
WO (1) WO2022008911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201911944D0 (en) 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
GB201915932D0 (en) 2019-11-01 2019-12-18 Reviral Ltd Pharmaceutical compounds
GB202010409D0 (en) 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
GB202102602D0 (en) 2021-02-24 2021-04-07 Reviral Ltd Pharmaceutical compounds
WO2024252355A1 (en) 2023-06-08 2024-12-12 Pfizer Inc. Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv
WO2025120500A1 (en) 2023-12-06 2025-06-12 Pfizer Inc. Benzodiazepine compounds as n-protein inhibitors
CN122580320A (zh) 2024-01-16 2026-08-14 辉瑞大药厂 作为n-蛋白抑制剂的苯二氮䓬吡唑甲酰胺类
CN121621343B (zh) * 2026-02-02 2026-05-15 云南大学 一种化合物在防控植物病原真菌尖孢镰刀菌上的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011052A (es) * 1999-04-30 2002-11-22 Univ Michigan Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas.
BR0314595A (pt) * 2002-09-20 2005-08-09 Arrow Therapeutics Ltd Uso de um derivado de benzodiazepina ou um sal farmaceuticamente aceitável deste, inalador ou nebulisador, produto, usos de um produto e de um composto ou sal farmaceuticamente aceitável deste, derivado de benzodiazepina, composto, e, composição farmacêutica
ATE410161T1 (de) 2003-05-02 2008-10-15 Elan Pharm Inc 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
GB0312365D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel 3-substituted-1, 4-benzodiazepines
US20070293482A1 (en) 2004-03-19 2007-12-20 Novartis Pharmaceuticals Corporation Process for Preparing Benzodiazepines
GB0406280D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Chemical compounds
GB0406282D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
GB0406279D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
US20070032475A1 (en) 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
TW201113262A (en) 2009-09-03 2011-04-16 Arrow Therapeutics Ltd Chemical compounds
WO2011151651A1 (en) 2010-06-03 2011-12-08 Arrow Therapeutics Limited Benzodiazepine compounds useful for the treatment of hepatitis c
WO2011151652A1 (en) 2010-06-03 2011-12-08 Arrow Therapeutics Limited Benzodiazepine compounds useful for the treatment of hepatitis c
GB201506448D0 (en) 2015-04-16 2015-06-03 Univ Durham An antimicrobial compound
MY197231A (en) * 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
GB201613942D0 (en) 2016-08-15 2016-09-28 Univ Of Durham The An antimicrobial compound
WO2018085378A1 (en) 2016-11-01 2018-05-11 Milliken & Company Leuco polymers as bluing agents in laundry care compositions
WO2018129287A1 (en) 2017-01-06 2018-07-12 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as rsv inhibitors
WO2018152413A1 (en) 2017-02-16 2018-08-23 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
KR101970214B1 (ko) * 2017-07-17 2019-08-27 이화여자대학교 산학협력단 유기금속 화합물, 이들의 자기 조립체 및 이를 포함한 종양 진단 또는 치료용 조성물
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
EP3781571B1 (en) * 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
WO2020190935A1 (en) 2019-03-18 2020-09-24 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
GB201911944D0 (en) 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
GB201915273D0 (en) * 2019-10-22 2019-12-04 Reviral Ltd Pharmaceutical compounds
GB201915932D0 (en) 2019-11-01 2019-12-18 Reviral Ltd Pharmaceutical compounds
GB202010409D0 (en) 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
GB202010408D0 (en) 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
MX2023000440A (es) 2023-04-13
KR20230035597A (ko) 2023-03-14
BR112023000142A2 (pt) 2023-01-31
GB202010409D0 (en) 2020-08-19
US12678446B2 (en) 2026-07-14
EP4178964A1 (en) 2023-05-17
WO2022008911A1 (en) 2022-01-13
US20230270751A1 (en) 2023-08-31
CN116075516A (zh) 2023-05-05
CN116075516B (zh) 2026-02-03
JP7840923B2 (ja) 2026-04-06
JP2023539985A (ja) 2023-09-21

Similar Documents

Publication Publication Date Title
AU2018244349B2 (en) Compounds that inhibit Mcl-1 protein
CA2880251C (en) Novel heteroaryl and heterocycle compounds, composition and methods thereof
JP6628930B1 (ja) Rsウイルス(rsv)複製の阻害活性を有するピペリジン置換ピラゾロ[1,5−a]ピリミジン誘導体
CA2927252C (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CA2944475C (en) Bicyclic-fused heteroaryl or aryl compounds
EP2991977B1 (en) C-linked heterocycloalkyl substituted pyrimidines and their uses
EP4182313A1 (en) Kras g12d inhibitors
AU2017382029B2 (en) Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-kinase inhibitors
JP7840923B2 (ja) 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体
DK3149008T3 (en) Specific protein kinase inhibitors
AU2019382504B2 (en) Cyclic ureas
EP4549438A1 (en) Five-membered and six-membered nitrogen-containing compound, and intermediate, preparation method and use thereof
CA3047212A1 (en) Tyrosine amide derivatives as rho- kinase inhibitors
CA2729045A1 (en) Pyrimidine compounds, compositions and methods of use
AU2018290511B2 (en) Dihydropyrimidine compounds and uses thereof in medicine
AU2007235487A1 (en) Deazapurines useful as inhibitors of janus kinases
CA2800079A1 (en) Macrocyclic compounds as trk kinase inhibitors
WO2015178955A1 (en) Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
CA3151232A1 (en) Pharmaceutical compounds
AU2018312836A1 (en) Novel heterocyclic compounds as CDK8/19 inhibitors
CA3158169A1 (en) Benzodiazepine derivatives for treating a respiratory syncytial virus (rsv) infection
AU2021290208B2 (en) Tricyclic compounds
JP2024545518A (ja) Cdk9阻害剤及びその使用
CA2963054C (en) Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv)
WO2025194074A1 (en) Kinase modulators and methods of use thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250616

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250616

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250620

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250620

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250827

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250827

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250827

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260616

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260616

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260623

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260727